Peritoneal cancer immunotherapy
Material peritoneal cancer immunotherapy methods: A retrospective study was carried out on series of patients admitted in the period June - March The duration of hospitalization was between 1 and 61 days, with an average of The data from observation peritoneal cancer immunotherapy, the operating protocols, pathology reports and follow-up files were collected and analyzed.
The most common complication was septic shock and mortality was 9. Average survival was 5.
Conclusion: PC-GI is a disease with a poor prognosis, posing difficulties in early diagnosis, establishing the surgical indication and protocol. Consistent advances in systemic and locoregional chemotherapy, surgical techniques, intraoperative radiotherapy, as well as immunotherapy are expected to improve prognosis.
Author Biographies I. Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. J Surg Oncol ; Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer.
Oncology ; Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. Nucl Med Commun ; Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
J Clin Oncol ; Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.
Ann Surg Oncol ; Cost of an intraperitoneal chemohyperthermia IPCH related to cytoreductive surgery. Ann Chir ; Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy HIPEC. Eur J Surg Oncol ; Onkologie ; Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis.
J BUON ; Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? Ann Surg ; Treatment of the peritoneal carcinomatosis by cytoreductive surgery peritoneal cancer immunotherapy intraperitoneal hyperthermic chemotherapy IHPC : postoperative morbidity and mortality and short-term follow-up.
Ann Ital Chir ;